PURPOSE: To assess clinical outcomes of high-dose rate interstitial brachytherapy (HIB) in localized penile carcinoma.
MATERIAL & METHODS: From 03/2006 to 08/2013, patients with biopsy-proven T1-T2 (< 4 cm) non-metastatic localized penile squamous cell carcinoma underwent HIB. Under general anaesthesia, after Foley catheter placement, needles were placed in the target volume using a dedicated template. Planification was carried out with a post-implant CT-scan to deliver a total dose of 36 Gy in 9 fractions over 5 days (in adjuvant setting) or 39 Gy in 9 fractions over 5 days (as monotherapy). Dose-volume adaptation was manually achieved using graphical optimization. Dosimetric data and clinical outcomes were retrospectively analyzed. Toxicities were graded using the CTC v4.0.
RESULTS: With a median follow-up of 27 months [5.1-83], 12 patients including 8 T1a, 3 T1b and 1 T2 N0 underwent HIB (sole therapy: 11 pts; adjuvant: 1 pt). The actuarial 5-year relapse-free, cause-specific and overall survival rates were 83%, 100% and 78% respectively. Comparing pre and post treatment evaluation, no IPSS or IIEF-5 changes were reported. Dermatitis was reported systematically 1 month after HIB including 6 G1, 5 G2 and 1 G3. Only 1 experienced long-term G3 successfully treated with hyperbaric oxygen therapy. One urethral meatus stenosis G3 required meatotomy.
CONCLUSION: In selected patients with T1-T2 localized penile cancer, HIB may be considered as an optional conservative therapy. Longer follow-up is needed to confirm these encouraging preliminary results.
Written by:
Rouscoff Y, Falk AT, Durand M, Gal J, Chand ME, Gautier M, Marsaud A, Chevallier D, Amiel J, Hannoun-Levi JM. Are you the author?
Reference: Radiat Oncol. 2014 Jun 19;9(1):142.
doi: 10.1186/1748-717X-9-142
PubMed Abstract
PMID: 24941956
UroToday.com Penile and Urethral Cancers Section
